The CiNTech project aims to establish and empower the first Technological Pole for Innovation, Translation, and Industrialization dedicated to complex injectable drugs, particularly innovative platforms incorporating various oncology therapeutic agents (small molecules, peptides, nucleic acids). This unique hub encompasses three centers focused on knowledge translation, analytical development, prototyping, and GMP manufacturing. Designed to have a profound impact on Portugal's economy and scientific innovation, it fosters synergistic cooperation between SMEs, non-SMEs, and National Science-Technology System, resulting in a highly differentiated portfolio benefiting patients and boosting high-tech exports. Work packages and their leaders WP1 - Project Management (Bluepharma) WP2 - Organizational Innovation, digital transformation and climate transition (JPM) WP3 - Research, Innovation & Translation (UC) WP4 - Development, process engineering and scale-up (Bluepharma) WP5 - Manufacturing of GMP batches (Bluepharma) WP6 - Human resources qualification (Bluepharma) WP7 - Dissemination, Exploitation, and Communication (UC)
Establishment and empowerment of the first Technological Pole for Innovation, Translation, and Industrialization dedicated to complex injectable drugs, particularly innovative platforms incorporating various oncology therapeutic agents (small molecules, peptides, nucleic acids).
Co-funded by Component C5 - Capitalisation and Business Innovation under the Portuguese Resilience and Recovery Plan, through the NextGenerationEU Fund.
Biotrend
Bluepharma
INL - International Iberian Nanotechnology Laboratory
JointSteel
JPM
C644865576-00000005
2022-09-17
2023-01-01
2025-12-31
We use cookies to improve your visit to our website.